Time latencies of  Helicobacter pylori  eradication after peptic ulcer and risk of recurrent ulcer, ulcer adverse events, and gastric cancer: a population-based cohort study

Sverdén, Emma; Brusselaers, Nele; Wahlin, Karl; Lagergren, Jesper

doi:10.1016/j.gie.2017.11.035

Cited by 29 publications

(21 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This study included 29,032 patients receiving H. pylori eradication therapy after PUD diagnosis in the years 2005 to 2013. The delay in H. pylori eradication time dependently increased the risk of recurrent ulcer, and even more so for complicated ulcers, starting from delays of 8‐30 days …”

Section: Helicobacter Pylori and Peptic Ulcer Diseasementioning

confidence: 99%

“…The delay in H. pylori eradication time dependently increased the risk of recurrent ulcer, and even more so for complicated ulcers, starting from delays of 8-30 days. 7 It has been assumed that NSAID intake may be related with asymptomatic or less symptomatic PUD and that the so-called silent ulcers are likely to present themselves as a complicated disease. Two recent studies have not proven this hypothesis.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Helicobacter pylori and nonmalignant upper gastrointestinal diseases

2018

View full text Add to dashboard Cite

The review of the most important recent publications concerning the relation of Helicobacter pylori with peptic ulcer disease (PUD), noninvestigated and functional dyspepsia, and gastroesophageal reflux disease (GERD) is presented. H. pylori remains the main etiopathogenetic factor in complicated and uncomplicated PUD. Nevertheless, the role of nonsteroidal anti-inflammatory drugs (NSAIDs) and aspirin is increasing. The novel data did not confirm that PUD caused by NSAIDs and aspirin is less symptomatic. The role of glucocorticoids, immunosuppressants, and antidepressants seems to be of some importance. Although the involvement of H. pylori in functional dyspepsia is controversial, several data support the importance of H. pylori-induced gastritis in the pathogenesis of dyspeptic symptoms. Recent interventional studies have reported that H. pylori eradication improves dyspepsia mainly in areas with a high prevalence of this bacterium. Novel data regarding the relation of gastrointestinal peptides, ghrelin and obestatin, with H. pylori infection are also presented. Intriguing findings support the involvement of the gastric microbiota in the causation of chronic functional dyspepsia. Finally, some data concerning negative, positive, or neutral associations of H. pylori with gastroesophageal reflux disease (GERD) were published. In this context, today there is no evidence indicating that H. pylori eradication could worsen the symptoms or the course of GERD.

show abstract

Section: Helicobacter Pylori and Peptic Ulcer Diseasementioning

confidence: 99%

mentioning

confidence: 99%

Helicobacter pylori and nonmalignant upper gastrointestinal diseases

2018

View full text Add to dashboard Cite

show abstract

“…Even though eradication therapy causes adverse drug reactions among 4% of patients, it can prevent infection from progressing to gastric mucosal atrophy, thereby reducing early‐stage gastric cancer . A population‐based study has revealed that delays in eradication therapy after peptic ulcer diagnosis increase the risk of recurrent ulcer in a time‐dependent manner . Helicobacter pylori eradication therapy can be beneficial in patients with other specific diseases, such as idiopathic thrombocytopenic purpura, mucosa‐associated lymphoid tissue lymphoma, and iron‐deficiency anemia .…”

Section: Introductionmentioning

confidence: 99%

Clinical background factors affecting outcomes of Helicobacter pylori eradication therapy in primary care

Yokota

Amenomori

et al. 2019

J of Gen and Family Med

View full text Add to dashboard Cite

Objective Few studies have reported the influence of clinical background factors on the outcome of Helicobacter pylori eradication therapy in primary care practice. We aimed to determine which clinical background factors influence the outcome of eradication therapy in a primary care setting. Methods This was a retrospective study of patients who received H pylori eradication therapy at Higashiohmi City Gamo Medical Center, Shiga, Japan, from January 2012 to December 2015. We investigated clinical background factors associated with success, failure, and self‐interruption of H pylori eradication therapy: patients’ age, gender, first‐ or second‐line treatment, reasons for receiving gastroenterological endoscopic examination, method of drug administration, and attending physicians’ age and their specialties. Results There were 369 patients (208 females, 161 male), with a mean age of 59 years (range 30‐88 years). The middle‐aged group (50‐69 years) was associated with successful eradication therapy compared with the young group (30‐49 years). The elderly group (>70 years) was associated with eradication therapy failure compared with the middle‐aged group. The young group was associated with self‐interruption of eradication therapy. There was a marginally significant association between male patients and self‐interruption. Older attending physicians (>50 years) were also associated with failure compared with younger physicians. There was no difference in outcome of eradication therapy between generalists and gastroenterology specialists. Conclusion We have identified clinical factors associated with success, failure, and self‐interruption of H pylori eradication therapy in a primary care setting.

show abstract

“…24 It is also seen that delaying H. pylori eradication enhances the risk of peptic ulcer recurrence and gastric malignancies. 25 Thus, it is prudent to treat and eradicate H. pylori infection promptly and appropriately to avoid peptic ulcers and ulcer-associated adverse events. H. pylori was first discovered by Robin Warren in 1979 and first cultured by Barry Marshall in 1982.…”

Section: Discussionmentioning

confidence: 99%

<p>Reevaluation of the Efficacy of First Line Regimen for <em>Helicobacter pylori</em></p>

Tariq¹,

Patel²,

Kamal³

et al. 2020

CEG

View full text Add to dashboard Cite

Background: Helicobacter pylori is a common cause of gastritis, peptic ulcer disease, and non-ulcer dyspepsia, and is also associated with gastric adenocarcinoma and mucosa associated lymphoid tissue lymphoma. Despite being known about for more than 30 years, finding an effective therapeutic strategy against it remains a challenge. Aim: There are no US studies evaluating the efficacy of a Levofloxacin based therapy for H. pylori infection. We here intend to study the efficacy of Levofloxacin based triple antibiotic regimen as compared to Clarithromycin based triple therapy and Bismuth based quadruple therapy in our patient population. Methods: This is a retrospective single center observational study. Patients with Helicobacter pylori infection who underwent treatment for H. pylori with one of the three therapies, i.e. Clarithromycin triple, Bismuth Quadruple or Levofloxacin triple, were included in the study and the eradication rates were compared. The confirmation of the H. pylori was done 4 weeks after the completion of anti-microbial therapy. Results: A total of 177 individuals underwent the H. pylori treatment in our retrospective review. Of these, 54% (n=97) of patients were treated with Clarithromycin based triple therapy (Group 1), 35% (n=63) were treated with Levofloxacin based regimen (Group 2), and the remaining 11% (n=17) were treated with Bismuth based quadruple therapy (Group 3). The eradication rates were significantly higher in patients treated with Clarithromycin based triple therapy as compared to Levofloxacin based triple therapy and Bismuth quadruple therapy (78.3% vs 49.2% vs 41.1% P=0.001). Conclusion: In conclusion, our study shows significantly lower eradication rates with Levofloxacin triple therapy among a selected US population. Thus, it may not be a good first-line therapy among this US population and the Clarithromycin based regimen may still be used successfully.

show abstract

Time latencies of Helicobacter pylori eradication after peptic ulcer and risk of recurrent ulcer, ulcer adverse events, and gastric cancer: a population-based cohort study

Abstract: Delays in H pylori eradication therapy after peptic ulcer diagnosis time-dependently increase the risk of recurrent ulcer, even more so for complicated ulcer, starting from delays of 8 to 30 days.

Cited by 29 publications

References 20 publications

Helicobacter pylori and nonmalignant upper gastrointestinal diseases

Helicobacter pylori and nonmalignant upper gastrointestinal diseases

Clinical background factors affecting outcomes of Helicobacter pylori eradication therapy in primary care

<p>Reevaluation of the Efficacy of First Line Regimen for <em>Helicobacter pylori</em></p>

Contact Info

Product

Resources

About